Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitor

This page shows the latest JAK inhibitor news and features for those working in and with pharma, biotech and healthcare.

FDA approves Incyte’s Opzelura for vitiligo

FDA approves Incyte’s Opzelura for vitiligo

It is also the only topical formulation of a Janus kinase (JAK) inhibitor approved in the US. ... An over-activity of the JAK signalling pathway is thought to further drive inflammation involved in the progression of vitiligo.

Latest news

More from news
Approximately 6 fully matching, plus 86 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    The decade-long $5.1bn alliance, announced in July, came on the heels of a long relationship between the two companies that had already yielded a late-stage candidate, JAK inhibitor ... and filgotinib’s anticipated launch this year meets expectations

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite ... checkpoint

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China). ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is highly selective for

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Viseven

Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...

Latest intelligence

Sustainability
Environment: where does the pharmaceutical industry stand?
...
The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...